Author

Kate L Li

Institution: Mayo Clinic

Observed institutions: Mayo Clinic, Actinium Pharmaceuticals (United States)

OpenAlex ID: A5111125792

131I-Apamistamab Improves Outcomes in Patients 65 Years and Older with Relapsed or Refractory AML

2024 · Rajneesh Nath, Stuart Seropian, et al. · Transplantation and Cellular Therapy · 3

131I-Apamistamab Effectively Achieved Durable Responses in Patients with R/R AML Irrespective of the Presence of Multiple High-Risk Factors

2023 · Stuart Seropian, James M. Foran, et al. · Blood · 1

Works count: 2

Citation count: 4

H-index: 1

I10-index: